TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35619283

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Incremental shuttle walk test (ISWT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sedentary patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: Higher NYHA functional class
Number of subjects: 48

Group type: COMPARATOR
Intervention: ISWT
Number of subjects: 48
Study: 34323130

Group type: EXPERIMENTAL
Intervention: Village Health Volunteer (VHV) program
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 344
Study: 35840893

Group type: EXPERIMENTAL
Intervention: Single cognitive training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Single motor training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Simultaneous cognitive-motor training
Number of subjects: 150
Study: 33378447

Group type: EXPERIMENTAL
Intervention: 0.8% metronidazole gel
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: SMS reminder and placebo gel
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 66
Study: 34192721

Group type: EXPERIMENTAL
Intervention: Ottawa scale
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chen scale
Number of subjects: 50
Study: 34097053

Group type: EXPERIMENTAL
Intervention: Intravenous rehydration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35666856

Group type: EXPERIMENTAL
Intervention: Goat Milk Based Infant Formula (GMF)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Cow Milk Formula (CMF)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Breast Fed (BF)
Number of subjects: 218
Study: 34762534

Group type: EXPERIMENTAL
Intervention: Laser-Assisted Drug Delivery (LADD) with 10% tranexamic acid solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Picosecond laser alone
Number of subjects: 10
Study: 32818951

Group type: EXPERIMENTAL
Intervention: Pharmacist introduction into the ambulatory kidney care model
Number of subjects: 25016

Group type: COMPARATOR
Intervention: Not prescribed a statin
Number of subjects: 25016

Group type: COMPARATOR
Intervention: Potentially inappropriate prescriptions
Number of subjects: 25016

Group type: COMPARATOR
Intervention: Rate of potentially inappropriate prescribing
Number of subjects: 25016
Study: 35867960

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) for patients with high total metabolic tumor volume
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD) for patients with high total metabolic tumor volume
Number of subjects: 170
Study: 35604680

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 32422456

Group type: EXPERIMENTAL
Intervention: Real rTMS treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 97
Study: 34921090

Group type: EXPERIMENTAL
Intervention: Cardiovascular preventive medication
Number of subjects: 21
Study: 32178668

Group type: EXPERIMENTAL
Intervention: Ropivacaine alone (1 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with meloxicam (0.2 mg/kg)
Number of subjects: 45
Study: 33128351

Group type: EXPERIMENTAL
Intervention: Disease modifying therapy
Number of subjects: 30023

Group type: EXPERIMENTAL
Intervention: Epidemiological studies
Number of subjects: 30023

Group type: EXPERIMENTAL
Intervention: Observational studies on effectiveness of disease modifying treatments
Number of subjects: 30023
Study: 32162530

Group type: EXPERIMENTAL
Intervention: Risk score system based on demographic and clinicopathological variables
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Risk score system
Number of subjects: 827
Study: 33145695

Group type: EXPERIMENTAL
Intervention: History of pressured sex (often)
Number of subjects: 1490

Group type: COMPARATOR
Intervention: History of verbal abuse
Number of subjects: 1490

Group type: COMPARATOR
Intervention: History of physical abuse
Number of subjects: 1490
Study: 33179978

Group type: EXPERIMENTAL
Intervention: Viewing larger body shapes
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Viewing varying body shapes
Number of subjects: 891
Study: 32454259

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 0
Study: 32085923

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) - 15 Gy in one fraction
Number of subjects: 22

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT) - 20 Gy in five fractions
Number of subjects: 22
Study: 36343847

Group type: EXPERIMENTAL
Intervention: Linerixibat 180 mg once daily
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Linerixibat 40 mg twice daily
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Linerixibat 90 mg twice daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Linerixibat (various doses)
Number of subjects: 147
Study: 34638611

Group type: EXPERIMENTAL
Intervention: EV-RIPC
Number of subjects: 30

Group type: COMPARATOR
Intervention: EV-naive
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 30
Study: 32040891

Group type: EXPERIMENTAL
Intervention: Listening to music, covering the PFT screen, or doing breathing meditation before PFTs
Number of subjects: 75

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 75
Study: 35854659

Group type: EXPERIMENTAL
Intervention: Supervised exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Home-based exercises
Number of subjects: 30
Study: 33577618

Group type: EXPERIMENTAL
Intervention: Adachi Rehabilitation Programme (ARP)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 35590291

Group type: EXPERIMENTAL
Intervention: WeChat mini‐program 'Clean Teeth' based on HAPA theory + care as usual
Number of subjects: 44

Group type: COMPARATOR
Intervention: Routine oral health education (Control)
Number of subjects: 44
Study: 34044562

Group type: EXPERIMENTAL
Intervention: Observation group (TXB2, 6‐k‐PGFla, BG levels)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control group (normal levels of TXB2, 6‐k‐PGFla, BG)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Combined detection of TXB2, 6‐k‐PGFla, and BG
Number of subjects: 216
Study: 32618134

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg tablets for 24 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 90
Study: 36266431

Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg administered twice daily for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 33782049

Group type: EXPERIMENTAL
Intervention: Netazepide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 36378543

Group type: EXPERIMENTAL
Intervention: IMT + CR
Number of subjects: 96

Group type: COMPARATOR
Intervention: CR
Number of subjects: 96
Study: 33121884

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine (10.9 mg of intrathecal 0.5% plain bupivacaine with 0.2 mg morphine)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (10.9 mg of intrathecal 0.5% hyperbaric bupivacaine with 0.2 mg morphine)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Plain bupivacaine
Number of subjects: 168

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine
Number of subjects: 168
Study: 32993573

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) Therapy
Number of subjects: 500
Study: 36342678

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Computer-Tailored Print Feedback (CTPF)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 483
Study: 33799302

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: Stent retrievers as primary treatment device
Number of subjects: 3077

Group type: COMPARATOR
Intervention: Control group (non-CCE patients)
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: Overall association of CCE with functional outcome
Number of subjects: 3077
Study: 32571396

Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise training
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Gym-based resistance exercise training
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 150
Study: 35537720

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 32236953

Group type: EXPERIMENTAL
Intervention: Licogliflozin (50 mg q.d.) with a 50% carbohydrate meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Licogliflozin (50 mg q.d.) with a 0% carbohydrate meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Psyllium 6 g or calcium carbonate 1 g supplementation
Number of subjects: 24
Study: 36477958

Group type: EXPERIMENTAL
Intervention: Filtek Z350 XT
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: FiltekTM Bulk‐fill
Number of subjects: 65

Group type: COMPARATOR
Intervention: Bulk-fill resin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional resin
Number of subjects: 65
Study: 34560319

Group type: EXPERIMENTAL
Intervention: Twice-daily iTBS (600 pulses)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Once-daily iTBS (1200 pulses)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 208
Study: 32893790

Group type: EXPERIMENTAL
Intervention: Bubble Continuous Positive Airway Pressure (bCPAP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nasal oxygen (Control)
Number of subjects: 120
Study: 35153479

Group type: EXPERIMENTAL
Intervention: Combination low-dose theophylline (100mg bd) and prednisone (5mg qd)
Number of subjects: 1487

Group type: COMPARATOR
Intervention: Theophylline (100mg bd) and prednisone-matched placebo
Number of subjects: 1487

Group type: COMPARATOR
Intervention: Double-matched placebo
Number of subjects: 1487
Study: 34027703

Group type: EXPERIMENTAL
Intervention: LARA wheelchair (n = 11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional exercises (n = 8)
Number of subjects: 19
Study: 33141883

Group type: EXPERIMENTAL
Intervention: Osteomyelitis treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Osteomyelitis
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wound healing
Number of subjects: 35

Group type: COMPARATOR
Intervention: Reulceration
Number of subjects: 35

Group type: COMPARATOR
Intervention: Readmission for DFIs
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 35
Study: 32381522

Group type: EXPERIMENTAL
Intervention: Remote electronic consent procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone consent procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person consent procedures
Number of subjects: 0
Study: 35761268

Group type: EXPERIMENTAL
Intervention: sFlt-1
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: sFlt-1/PIGF ratio (continuous)
Number of subjects: 370

Group type: COMPARATOR
Intervention: PIGF
Number of subjects: 370

Group type: COMPARATOR
Intervention: sFlt-1/PIGF ratio as cut-off at 38
Number of subjects: 370
Study: 33839731

Group type: EXPERIMENTAL
Intervention: 30-min walk
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 40
Study: 35712800

Group type: EXPERIMENTAL
Intervention: Bromocriptine quick release (BCQR) titrated from 0.8 mg to 1.6 mg to 3.2 mg (minimum dose 1.6 mg) for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32789431

Group type: EXPERIMENTAL
Intervention: Waiting time estimates provided to the intervention group
Number of subjects: 100

Group type: COMPARATOR
Intervention: No waiting time estimates provided to the control group
Number of subjects: 100
Study: 33978167

Group type: COMPARATOR
Intervention: 60 mg Fe with 0 mg folic acid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 60 mg Fe with 0.4 mg folic acid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 60 mg Fe with 2.8 mg folic acid
Number of subjects: 311
Study: 32895004

Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2337

Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 2337
Study: 35652772

Group type: EXPERIMENTAL
Intervention: ACB‐IPACK block (30 mL bupivacaine 0.25%)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adductor canal block (ACB) (20 mL bupivacaine 0.25%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ACB‐IPACK block
Number of subjects: 80

Group type: COMPARATOR
Intervention: ACB
Number of subjects: 80
Study: 34730495

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 32524582

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (planned cesarean section)
Number of subjects: 308
Study: 36331326

Group type: EXPERIMENTAL
Intervention: Inclisiran (284 mg administered on Days 1, 90, and every 6 months thereafter for 18 months)
Number of subjects: 3655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3655

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 3655
Study: 32972900

Group type: EXPERIMENTAL
Intervention: Binary Disability Question (BDQ)
Number of subjects: 2807

Group type: COMPARATOR
Intervention: Washington Group Short Set (WGSS1)
Number of subjects: 2807

Group type: COMPARATOR
Intervention: Washington Group Short Set (WGSS2)
Number of subjects: 2807
Study: 32284448

Group type: EXPERIMENTAL
Intervention: Foot reflexology massage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Simple massage
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 35032224

Group type: EXPERIMENTAL
Intervention: Pedal pump lymphatic technique
Number of subjects: 17

Group type: COMPARATOR
Intervention: Passive supine recovery
Number of subjects: 17
Study: 32032333

Group type: EXPERIMENTAL
Intervention: CoBRA audit tool
Number of subjects: 17956
Study: 35946107

Group type: EXPERIMENTAL
Intervention: Baseline serum neurofilament light chain (sNfL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower baseline volume of the transverse temporal gyrus
Number of subjects: 0
Study: 34126308

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy for Anhedonia (BATA)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 73
Study: 35863958

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Technique Guide (TG) training
Number of subjects: 22
Study: 34256199

Group type: EXPERIMENTAL
Intervention: Dual transcranial direct current stimulation (dual tDCS) and modified constraint-induced movement therapy (mCIMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham dual tDCS and modified constraint-induced movement therapy (mCIMT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dual tDCS and mCIMT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham dual tDCS and mCIMT
Number of subjects: 30
Study: 36435738

Group type: COMPARATOR
Intervention: Adjuvant intravesical mitomycin C (MMC) at normothermia (control)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Adjuvant intravesical mitomycin C (MMC) at 43 °C for 30 min
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Adjuvant intravesical mitomycin C (MMC) at 43 °C for 60 min
Number of subjects: 319
Study: 33610174

Group type: EXPERIMENTAL
Intervention: BRIDGE program (new rehabilitation program)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Traditional rehabilitation program (control)
Number of subjects: 357
Study: 36104267

Group type: EXPERIMENTAL
Intervention: Sodium benzoate 250 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sodium benzoate 500 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sodium benzoate 1000 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sodium benzoate 2000 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sodium benzoate (all doses)
Number of subjects: 4
Study: 33059710

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33382916

Group type: EXPERIMENTAL
Intervention: LY2775240 (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Apremilast (30 mg)
Number of subjects: 0
Study: 32068366

Group type: EXPERIMENTAL
Intervention: Nonsedation group
Number of subjects: 700

Group type: COMPARATOR
Intervention: Sedation group
Number of subjects: 700
Study: 36013087

Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg after induction and 15 min before the end of surgery)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study: 36074392

Group type: EXPERIMENTAL
Intervention: Erector spine plane block (ESPB)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Local anesthetic block (BAL)
Number of subjects: 92
Study: 33813948

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Both options (intensive lifestyle change and metformin)
Number of subjects: 515

Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Patients >60 years old
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 515
Study: 32302018

Group type: EXPERIMENTAL
Intervention: Intracervical balloon placement
Number of subjects: 300

Group type: COMPARATOR
Intervention: Intrauterine balloon placement
Number of subjects: 300
Study: 35266189

Group type: EXPERIMENTAL
Intervention: Tät®II app for self-management of UUI and MUI
Number of subjects: 123
Study: 34408675

Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy (iCBT) plus treatment-as-usual (TAU)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) only
Number of subjects: 81
Study: 35239196

Group type: EXPERIMENTAL
Intervention: Branded Guidelines (n = 26)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Unbranded Guidelines (n = 20)
Number of subjects: 46
Study: 34097688

Group type: EXPERIMENTAL
Intervention: Gender-neutral HPV vaccination (Arm A)
Number of subjects: 8022

Group type: EXPERIMENTAL
Intervention: Girls-only HPV vaccination (Arm B)
Number of subjects: 8022

Group type: COMPARATOR
Intervention: No HPV vaccination (Arm C)
Number of subjects: 8022
Study: 34817321

Group type: EXPERIMENTAL
Intervention: Danzhi Xiaoyao powder (DXP)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Danzhi Xiaoyao powder (DXP) + amlodipine
Number of subjects: 252
Study: 33372439

Group type: EXPERIMENTAL
Intervention: Interferential current therapy (IFC), active therapy, three times per week for four weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham IFC stimulation (Control)
Number of subjects: 62
Study: 35413872

Group type: EXPERIMENTAL
Intervention: HBM-based text messages sent regularly for 48 weeks
Number of subjects: 518

Group type: COMPARATOR
Intervention: Standard text message sent to parents in the control group in the first week
Number of subjects: 518
Study: 33664568

Group type: EXPERIMENTAL
Intervention: PRIDE intervention (social, physical, and cognitive domains supported by a facilitator over three sessions)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 92
Study: 35482769

Group type: EXPERIMENTAL
Intervention: Exercise intervention (6-month randomized controlled trial)
Number of subjects: 131
Study: 33509911

Group type: EXPERIMENTAL
Intervention: 11 for Health in Denmark programme
Number of subjects: 3127
Study: 34791009

Group type: EXPERIMENTAL
Intervention: Plant sterols (PSs) 2 g/d for 28 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 33023785

Group type: EXPERIMENTAL
Intervention: 4-weekly BTA treatment
Number of subjects: 263

Group type: COMPARATOR
Intervention: 12-weekly BTA treatment
Number of subjects: 263
Study: 34109872

Group type: EXPERIMENTAL
Intervention: Culturally sensitive interventions (specific details not provided)
Number of subjects: 9
Study: 33619835

Group type: EXPERIMENTAL
Intervention: α-galactosidase (1200 GaIU/meal)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 35688164

Group type: EXPERIMENTAL
Intervention: tixagevimab–cilgavimab 600 mg (two consecutive 3 mL intramuscular injections, 300 mg tixagevimab and 300 mg cilgavimab)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: tixagevimab–cilgavimab 600 mg
Number of subjects: 910
Study: 33845880

Group type: EXPERIMENTAL
Intervention: GPR + a smartphone app
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GPR alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 32652133

Group type: EXPERIMENTAL
Intervention: Best practices plus financial incentives
Number of subjects: 60

Group type: COMPARATOR
Intervention: Best practices alone
Number of subjects: 60
Study: 35565929

Group type: EXPERIMENTAL
Intervention: Iso-caloric high-fat diet (HFD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Iso-caloric high-carbohydrate diet (HCD)
Number of subjects: 15
Study: 32957335

Group type: EXPERIMENTAL
Intervention: Jaw Opening Exercise (JOE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Head Lift Exercise (HLE)
Number of subjects: 30